These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 10631622)

  • 21. Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting.
    Mafauzy M
    Diabetes Res Clin Pract; 2002 Oct; 58(1):45-53. PubMed ID: 12161056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes.
    Damsbo P; Marbury TC; Hatorp V; Clauson P; Müller PG
    Diabetes Res Clin Pract; 1999 Aug; 45(1):31-9. PubMed ID: 10499883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of prandial glucose regulation with repaglinide in addressing the problem of hypoglycemia in the treatment of type 2 diabetes.
    Owens D
    J Assoc Physicians India; 2001 Jan; 49 Spec No():54-61. PubMed ID: 11235607
    [No Abstract]   [Full Text] [Related]  

  • 24. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan.
    Bakiner O; Ertorer ME; Bozkirli E; Tutuncu NB; Demirag NG
    Acta Diabetol; 2009 Mar; 46(1):63-5. PubMed ID: 18825302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repaglinide induced acute hepototoxicity.
    Jaiswal S; Mehta R; Musuku M; Tran L; McNamee W
    JNMA J Nepal Med Assoc; 2009; 48(174):162-4. PubMed ID: 20387361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of repaglinide, administered two or three times daily for 3 months, on glycaemic control in Japanese patients with type 2 diabetes mellitus.
    Kamiyama H; Aoki K; Nakajima S; Shinoda K; Kamiko K; Taguri M; Terauchi Y
    J Int Med Res; 2014 Oct; 42(5):1150-60. PubMed ID: 25015763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beta-cell response during a meal test: a comparative study of incremental doses of repaglinide in type 2 diabetic patients.
    Cozma LS; Luzio SD; Dunseath GJ; Underwood PM; Owens DR
    Diabetes Care; 2005 May; 28(5):1001-7. PubMed ID: 15855557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application.
    Rosak C; Hofmann U; Paulwitz O
    Diabetes Nutr Metab; 2004 Jun; 17(3):137-42. PubMed ID: 15334790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas.
    Landgraf R; Bilo HJ; Müller PG
    Eur J Clin Pharmacol; 1999 May; 55(3):165-71. PubMed ID: 10379630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical study of repaglinide efficacy and safety in type 2 diabetes mellitus patients with blood glucose levels inadequately controlled by sitagliptin.
    Kawamori R; Kaku K; Hanafusa T; Ioriya K; Kageyama S; Hotta N
    J Diabetes Investig; 2016 Mar; 7(2):253-9. PubMed ID: 27042279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Severe hypoglycemia from clarithromycin-repaglinide drug interaction.
    Khamaisi M; Leitersdorf E
    Pharmacotherapy; 2008 May; 28(5):682-4. PubMed ID: 18447665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with Type 2 diabetes.
    Landgraf R; Frank M; Bauer C; Dieken ML
    Int J Obes Relat Metab Disord; 2000 Sep; 24 Suppl 3():S38-44. PubMed ID: 11063283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review.
    Johansen OE; Birkeland KI
    Am J Cardiovasc Drugs; 2007; 7(5):319-35. PubMed ID: 17953471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhancement of early- and late-phase insulin secretion and insulin sensitivity by the combination of repaglinide and metformin in type 2 diabetes mellitus.
    Rudovich NN; Leyck Dieken MG; Rochlitz H; Pfeiffer AF
    Exp Clin Endocrinol Diabetes; 2004 Jul; 112(7):395-400. PubMed ID: 15239026
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment.
    Schumacher S; Abbasi I; Weise D; Hatorp V; Sattler K; Sieber J; Hasslacher C
    Eur J Clin Pharmacol; 2001 May; 57(2):147-52. PubMed ID: 11417447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repaglinide dose response? A clinician's viewpoint.
    Strange P; Goldberg RB
    Diabetes Technol Ther; 2000; 2(1):119-21. PubMed ID: 11467310
    [No Abstract]   [Full Text] [Related]  

  • 37. Nateglinide versus repaglinide for type 2 diabetes mellitus in China.
    Li C; Xia J; Zhang G; Wang S; Wang L
    Acta Diabetol; 2009 Dec; 46(4):325-33. PubMed ID: 19183841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic profiles of repaglinide in elderly subjects with type 2 diabetes.
    Hatorp V; Huang WC; Strange P
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1475-8. PubMed ID: 10199798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An open label comparative study of glimepiride versus repaglinide in type 2 diabetes mellitus Muslim subjects during the month of Ramadan.
    Anwar A; Azmi KN; Hamidon BB; Khalid BA
    Med J Malaysia; 2006 Mar; 61(1):28-35. PubMed ID: 16708731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Repaglinide and diabetes: new preparation. No better than glucose-lowering sulphonamides.
    Prescrire Int; 2001 Feb; 10(51):9-11. PubMed ID: 11503861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.